METAFINES
MetaFines is researching and developing anti-cancer drugs using cancer metabolism.
METAFINES
Industry:
Biotechnology Health Care Medical
Founded:
2018-10-08
Address:
Seongnam, Kyonggi-do, South Korea
Country:
South Korea
Website Url:
http://www.metafines.com
Status:
Active
Contact:
+82 031-755-5569
Email Addresses:
[email protected]
Total Funding:
29 B KRW
Investors List
Meritz Capital
Meritz Capital investment in Series B - MetaFines
SNS-Investment
SNS-Investment investment in Series B - MetaFines
Meritz Securities
Meritz Securities investment in Series B - MetaFines
DSC Investment
DSC Investment investment in Series B - MetaFines
BMI KOREA
BMI KOREA investment in Series B - MetaFines
Prodigy Investment
Prodigy Investment investment in Series B - MetaFines
IP Ventures
IP Ventures investment in Series B - MetaFines
Korea Investment Securities
Korea Investment Securities investment in Series B - MetaFines
IBK Capital
IBK Capital investment in Series B - MetaFines
BMI KOREA
BMI KOREA investment in Series A - MetaFines
Official Site Inspections
http://www.metafines.com
- Host name: naver772.naver.com
- IP address: 211.218.150.116
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "MetaFines"
METAFINES
MetaFines Corp. , as the company name suggests, is a company that is researching and developing excellent anti-cancer drugs using cancer metabolism (cancer metabolism drugs).See details»
METAFINES
Organization. CEO. Division of Management Support. Finance. HR / Accounting. Division of Strategy Planning. Business Development. Division of R&D. ... Division of RA & Clinical Trials. โฆSee details»
METAFINES
MetaFines Corp. , was established in 2018 and is developing a โlow-toxic cancer metabolism drugsโ through the expansion and reorganization of indications for off-label drugs for incurable โฆSee details»
MetaFines - Crunchbase Company Profile & Funding
MetaFines is a biopharma firm that creates anticancer medications with the goal of preventing the spread of cancer. By extending and reconfiguring the โฆSee details»
Meta Fines Company Profile 2024: Valuation, Funding โฆ
Information on valuation, funding, cap tables, investors, and executives for Meta Fines. Use the PitchBook Platform to explore the full profile.See details»
Metafines.Co.Ltd. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Metafines.Co.Ltd. of Seongnam, Gyeonggi. Get the latest business insights from Dun & โฆSee details»
MetaFines - Funding, Financials, Valuation & Investors - Crunchbase
MetaFines is researching and developing anti-cancer drugs using cancer metabolism.See details»
MetaFines - Crunchbase
MetaFines is researching and developing anti-cancer drugs using cancer metabolism.See details»
MetaFines - Products, Competitors, Financials, Employees, โฆ
MetaFines focuses on the development of metabolic anticancer drugs within the pharmaceutical industry. The company specializes in creating novel pharmacological compositions that disrupt โฆSee details»
MF-02 - Drug Targets, Indications, Patents - Synapse - Patsnap
MF-02, Initially developed by Metafines Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Neoplasms, Active Indication: Solid tumor, Active Org.: Metafines Co., Ltd..See details»
ASCA-101 - Drug Targets, Indications, Patents - Synapse - Patsnap
ASCA-101: a Apoptosis stimulants Drug, Initially developed by Metafines Co., Ltd., Now, its global highest R&D status is Phase 1, Mechanism: Apoptosis stimulants, Therapeutic Areas: โฆSee details»
MF-03 - Drug Targets, Indications, Patents - Synapse
Understand key drug designations in just a few clicks with Synapse. MF-03, Initially developed by Metafines Co., Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: โฆSee details»
MetaFines - Tech Stack, Apps, Patents & Trademarks - Crunchbase
MetaFines is researching and developing anti-cancer drugs using cancer metabolism.See details»
METAFINES
MetaFines Corp. incorporated. 12 ~ 19.01 โSeries Aโ funding completed. 2019 01. Certified for Venture company. 07. Registration of domestic patent / Initiation of Toxicity study for โฆSee details»
MetaFines - VentureRadar
Website: http://www.metafines.com/ Develops 'ASCA101', a metabolic anti-cancer drug that disrupts cancer cell processes and is less susceptible to drug resistance, effectively inhibiting โฆSee details»
๋ฉํํ์ธ์ฆ - metafines.com
๋ฉํํ์ธ์ฆ - metafines.com ... ๋ฉํํ์ธ์ฆSee details»
ASCA 101 - AdisInsight - Springer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. ASCA 101 is a repurposed metabolic anti-cancer drug being developed by โฆSee details»
Series B - MetaFines - 2022-04-28 - Crunchbase
Apr 28, 2022ย ยท Tech in Asia โ Weekly update: Korean biotech firm MetaFinesโ $160m raise makes big splash News โข Apr 28, 2022 Metafinz attracts 20 billion won Series B investmentSee details»
MF-04 - Drug Targets, Indications, Patents - Synapse
MF-04, Initially developed by Metafines Co., Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Other Diseases, Active Indication: Cachexia, Active Org.: Metafines Co., โฆSee details»
MetaFines Stock Price, Funding, Valuation, Revenue ... - CB Insights
Apr 28, 2022ย ยท See MetaFines funding rounds, investors, investments, exits and more. Evaluate their financials based on MetaFines's post-money valuation and revenue.See details»